Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Noncytotoxic thiocolchicine derivatives useful as muscle relaxants

Nov. 10, 1998

Compounds acting on metabotropic glutamate receptors disclosed by Lilly

Nov. 10, 1998

Novel compounds from ADIR acting on the dopaminergic system

Nov. 10, 1998

New 5-HT1A receptor antagonist from Astra Arcus undergoes extensive preclinical testing

Nov. 9, 1998

Neuroprotective agents with dual NOS-inhibitory and antioxidant effects synthesized at French lab

Nov. 9, 1998

NPS-2390: representative of a novel class of potent and selective group I mGluR antagonists

Nov. 9, 1998

In vitro and in vivo pharmacology of CP-465022 presented at neuroscience meeting

Nov. 9, 1998

Novel proteasome inhibitor effective in animal model of stroke

Nov. 9, 1998

Effects of new free radical scavenger MDL-100002 in embolic stroke

Nov. 9, 1998

Centrally selective nAChR ligand from R.J. Reynolds considered Alzheimer's disease candidate

Nov. 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...